Aerosol research instrument company Inhalation Sciences (ISAB) has announced the formation of a new scientific advisory board, which will begin meeting on June 1, 2021 to discuss how the company’s PreciseInhale laboratory aerosol dosing system can be used once it has been validated for clinical use. Members of the new scientific advisory board include Carsten Ehrhardt of Trinity College; Per Wollmer of Lund University; Martin Wehling of the University of Heidelberg; and Gary Pitcairn of GRP Consulting.
The company announced in 2019 that it was raising money to finance a study of PreciseInhale in humans and now says that it submitted a clinical trial application for the study at the end of March 2021 and expects it to be complete by the end of 2021. According to ISAB, PreciseInhale would be the first aerosol generator available for use all the way from discovery through to Phase 1 clinical trials.
ISAB CEO Manoush Masarrat commented, “At Inhalation Sciences, it is paramount for us to be at the forefront of the inhalation research world. Our aim with the engagement of our new scientific advisory board is to transform their expertise and valuable input into more targeted new product development, hence accelerating the innovation rate.”
The company announced in October 2020 that it had been granted a US patent for the PreciseInhale system and recently announced that it had taken steps to expand its business in the US.
Read the ISAB press release.
